An ongoing trial of a dendritic cell (DC) vaccine transduced with an adenovirus expressing the extracellular and transmembrane domains of HER2, which cures mice of HER2+ tumors by inducing antibodies, is resulting in some complete and partial responses and stable disease in close to 50% of vaccinated patients with advanced metastatic HER2-expressing cancers who have failed standard therapies (Maenget al., manuscript in preparation). Here, ERBB2 is linked to cancer.